ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
DeltaZIP DeltaZIP 2 minutes ago
Looks like old share will stay but new shares will be issued thus diluting OS by about 15X. Shares outstanding go from about 2B to 32B after the restructuring from the rehabilitation plan if all is subscribed for debt conversion and shares offered to employees / existing shareholders. So trading aga
TAWNF
joe botts joe botts 2 minutes ago
You are welcome!
zerosnoop zerosnoop 3 minutes ago
EXPECTED OUTCOME

POSSIBLE SCENARIOS, DIFFERENT APPLICATIONS, SAME OUTSTANDING RESULTS

The AOT reduces pressure drop, increases flow volume, and minimizes power consumption.

AOT’s success lies in its ability to optimize crude oil transportation, making it
QSEP
Alpha14 Alpha14 4 minutes ago
Hmbl recently ran to .004. With the change in administration and the fact that these short positions have been on for years they have to cover to take profit an even out the books to adjust to the new administrations policies. FOXO Hass assumed RNVA debt. There are billions of shares that have been
FOXO RNVA
zerosnoop zerosnoop 4 minutes ago
But wait, according to the “experts”, I thought this was supposed to be just a “simple leak test” ? Wonder why they would need to run the device at 40KV for a “simple leak test?” I guess we can also throw the “going against the laws of mother nature” claim out the window as well (I still laugh at th
QSEP
zerosnoop zerosnoop 4 minutes ago
Hmm Saudi Arabia, could that be with Saudi Aramco ? The PROVEN AOT is going GLOBAL

This is why I do my own d/d. I only take advice from professionals who know what they are talking about & who know how to read and understand public filings.

As a result of initial custom
QSEP
zerosnoop zerosnoop 5 minutes ago
Three Revenue Silos: A Comprehensive Financial Framework

This agreement outlines a robust three-tier revenue model, consisting of:

1. Upfront Payments: Initial financial commitments that secure the deployment of the AOT units.

2. Sales and Lease Agreement
QSEP
jimr1717 jimr1717 6 minutes ago
“ Our existing stockholders will experience significant dilution from the sale of our common stock pursuant to this Registration Statement.

The sale of our common stock in accordance with the Registration Statement will have a dilutive impact on our shareholders. As a result, the mar
ATMH
SPARK'S FLY SPARK'S FLY 6 minutes ago
No need to pump when you have a wall with dmpers & bottom feeders. This will be .02-.05 when the BOZOS let ot run.
SRMX
BIG BALLER BIG BALLER 6 minutes ago
WELCOME 2 DA $OBJKT #OBJKTCOIN BOARD!!! ;] AIRDROP in PROGRESS!!!! >_> WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
https://www.geckoterminal.com/solana/pools/3PcDMjy2UGVXZ6u4SeWrpTnB78Xi4ieKEp3tsCcXr2zR
[yt]zazofh844m8[/yt]
OBJKT
zerosnoop zerosnoop 6 minutes ago
we are proud to report that the AOT works at a full voltage of 40KV, well beyond the treatment field.
QSEP
Hopeforthefuture3 Hopeforthefuture3 6 minutes ago
Xmaster, I would hope that people here are at least smart enough to know that to take a tax loss the shares must be in a taxable account. If not then they really need a broker to guide them.
For those that are this ignorant? shares held in a Roth or traditional IRA or 401k or 403b account are
NWBO
zerosnoop zerosnoop 7 minutes ago
I notice the paid bashers, tax cheats, fraudsters, grubs, uneducated fools with a low IQ & compulsive liars are getting more desperate with their nonsense. The short squeeze is fast approaching. The PROVEN AOT is going GLOBAL.

NAKED SHORT SELLING gets reported differently & isn't part
QSEP
zerosnoop zerosnoop 7 minutes ago
The below is so TRUE in regards to QSEP

A stock basher is someone who manipulates the market to cause a drop in asset prices.

Stock bashers disseminate misinformation in the hopes that investors will believe the false claims and sell their stock before the price drops.
QSEP
WinstonCup WinstonCup 9 minutes ago
Pitiful volume average.
WDLF
fza fza 10 minutes ago
First off, those are the words of the Scumbag CEO, and not Mr Kumar.


You are right and I stand corrected. By the way it is Dr. not Mr. In regards to the predictions, Kim using "expect" is positive none the less. I look forward to 54+/- days into next year. But thanks for
KBLB
JFR161162 JFR161162 10 minutes ago
Gary, 
Bankers only invite companies that are clients or have the potential to generate revenues in the short term.
Since NWBO raise $ internally (for now) there's ZERO chance they will be invited to such conferences before they get news from approval/partnership.
Uplisting is a
NWBO
ScamPolice63142 ScamPolice63142 10 minutes ago
HAHAHA! I hope they got the premium package: https://fitterlaw.com/pricing/
NSAV
krab krab 10 minutes ago
Lets hope next week the whales hear your horn, and both FnF surpasses the $3.60
FNMA
dinogreeves dinogreeves 10 minutes ago
7-8 dollars next week.
QBTS
dinogreeves dinogreeves 12 minutes ago
I am super bullish on SMCI, but I would definitely like to see share buyback at some point before the audit report comes out. 250-500 million dollar buy back will send the shorts running for the hills.
SMCI
badshah badshah 12 minutes ago
Let me remind everyone, for I have been in this situation many times before...I even played a small part with some folks in a movie called "Wall Street Fraud" decades back... the value of RNVA and/or FOXO has nothing to do with their business...it is singularly in the fact that 100s of billions of n
FOXO RNVA
zdog1954 zdog1954 12 minutes ago
Thanks Ted, your post got me to find and rewatch the 2021 ASM.  It is great to see all the things Dr. Lebby talked about then happening now with their technology. At this ASM he began to talk about foundry partnering and creating foundry PDK's for mass production. It seemed clear to me he was talkin
ASM

Your Recent History

Delayed Upgrade Clock